1932

Abstract

More than 750,000 people in the United States died from an overdose between 1999 and 2018; two-thirds of those deaths involved an opioid. In this review, we present trends in opioid overdose rates during this period and discuss how the proliferation of opioid prescribing to treat chronic pain, changes in the heroin and illegally manufactured opioid synthetics markets, and social factors, including deindustrialization and concentrated poverty, contributed to the rise of the overdose epidemic. We also examine how current policies implemented to address the overdose epidemic may have contributed to reducing prescription opioid overdoses but increased overdoses involving illegal opioids. Finally, we identify new directions for research to understand the causes and solutions to this critical public health problem, including research on heterogeneous policy effects across social groups, effective approaches to reduce overdoses of illegal opioids, and the role of social contexts in shaping policy implementation and impact.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-publhealth-090419-102727
2021-04-01
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/publhealth/42/1/annurev-publhealth-090419-102727.html?itemId=/content/journals/10.1146/annurev-publhealth-090419-102727&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Alexander MJ, Kiang MV, Barbieri M 2018. Trends in black and white opioid mortality in the United States, 1979–2015. Epidemiology 29:707–15
    [Google Scholar]
  2. 2. 
    Alinsky RH, Hadland SE, Matson PA, Cerdá M, Saloner B 2020. Adolescent-serving addiction treatment facilities in the United States and the availability of medications for opioid use disorder. J. Adolesc. Health 67:542–49
    [Google Scholar]
  3. 3. 
    Alinsky RH, Zima BT, Rodean J, Matson PA, Larochelle MR et al. 2020. Receipt of addiction treatment after opioid overdose among Medicaid-enrolled adolescents and young adults. JAMA Pediatr 174:e195183
    [Google Scholar]
  4. 4. 
    Am. Acad. Pain Med., Am. Pain Soc 1997. The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin. J. Pain 13:6–8
    [Google Scholar]
  5. 5. 
    Andrilla CHA, Moore TE, Patterson DG, Larson EH 2019. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J. Rural Health 35:108–12
    [Google Scholar]
  6. 6. 
    Aronowitz SV, Laurent J. 2016. Screaming behind a door: the experiences of individuals incarcerated without medication-assisted treatment. J. Correct. Health Care 22:98–108
    [Google Scholar]
  7. 7. 
    Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A et al. 2014. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int. J. Epidemiol. 43:235–48
    [Google Scholar]
  8. 8. 
    Atkins DN, Durrance CP, Kim Y 2019. Good Samaritan harm reduction policy and drug overdose deaths. Health Serv. Res. 54:407–16
    [Google Scholar]
  9. 9. 
    Autor D, Dorn D, Hanson G 2019. When work disappears: manufacturing decline and the falling marriage market value of young men. Am. Econ. Rev. Insights 1:161–78
    [Google Scholar]
  10. 10. 
    Autor DH, Duggan MG. 2006. The growth in the Social Security Disability rolls: a fiscal crisis unfolding. J. Econ. Perspect. 20:71–96
    [Google Scholar]
  11. 11. 
    Baker DD, Jenkins AJ. 2008. A comparison of methadone, oxycodone, and hydrocodone related deaths in Northeast Ohio. J. Anal. Toxicol. 32:165–71
    [Google Scholar]
  12. 12. 
    Bartholomew TS, Nakamura N, Metsch LR, Tookes HE 2020. Syringe services program (SSP) operational changes during the COVID-19 global outbreak. Int. J. Drug Policy 83:102821
    [Google Scholar]
  13. 13. 
    Becker WC, Fiellin DA. 2020. When epidemics collide: coronavirus disease 2019 (COVID-19) and the opioid crisis. Ann. Intern. Med. 173:59–60
    [Google Scholar]
  14. 14. 
    Beletsky L. 2019. America's favorite antidote: drug-induced homicide in the age of the overdose crisis. Utah Law Rev 4:4
    [Google Scholar]
  15. 15. 
    Beletsky L, Davis CS. 2017. Today's fentanyl crisis: Prohibition's Iron Law, revisited. Int. J. Drug Policy 46:156–59
    [Google Scholar]
  16. 16. 
    Binswanger IA, Blatchford PJ, Mueller SR, Stern MF 2013. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann. Intern. Med. 159:592–600
    [Google Scholar]
  17. 17. 
    Blanco C, Compton WM, Volkow ND 2020. Opportunities for research on the treatment of substance use disorders in the context of COVID-19. JAMA Psychiatry In press. https://doi.org/10.1001/jamapsychiatry.2020.3177
    [Crossref] [Google Scholar]
  18. 18. 
    Blumenstein R, Schukar A. 2020. Coming home to a Michigan county where life has shifted. New York Times March 9. https://www.nytimes.com/2020/03/09/us/michigan-primary-election.html
    [Google Scholar]
  19. 19. 
    Bohnert ASB, Guy GP Jr., Losby JL 2018. Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention's 2016 Opioid Guideline. Ann. Intern. Med. 169:367–75
    [Google Scholar]
  20. 20. 
    Bronson J, Stroop J, Zimmer S, Berzofsky M 2017. Drug use, dependence and abuse among state prisoners and jail inmates, 20072009 Rep., Bur. Justice Stat., US Dep. Justice Washington, DC:
    [Google Scholar]
  21. 21. 
    Brown E, Wehby GL. 2019. Economic conditions and drug and opioid overdose deaths. Med. Care Res. Rev. 76:462–77
    [Google Scholar]
  22. 22. 
    Brown GW, Harris TO. 1989. Life Events and Illness New York: Guilford
  23. 23. 
    Carnide N, Hogg-Johnson S, Côté P, Irvin E, Van Eerd D et al. 2017. Early prescription opioid use for musculoskeletal disorders and work outcomes: a systematic review of the literature. Clin. J. Pain 33:647–58
    [Google Scholar]
  24. 24. 
    Case A, Deaton A. 2015. Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. PNAS 112:15078–83
    [Google Scholar]
  25. 25. 
    CDC (Cent. Dis. Control Prev.) 2020. U.S. opioid prescribing rate maps Updated March 5, CDC Atlanta: https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html
  26. 26. 
    Cerdá M, Santaella J, Marshall BDL, Kim JH, Martins SS 2015. Nonmedical prescription opioid use in childhood and early adolescence predicts transitions to heroin use in young adulthood: a national study. J. Pediatr. 167:605–12.e2
    [Google Scholar]
  27. 27. 
    Chisholm-Burns MA, Spivey CA, Sherwin E, Wheeler J, Hohmeier K 2019. The opioid crisis: origins, trends, policies, and the roles of pharmacists. Am. J. Health Syst. Pharm. 76:424–35
    [Google Scholar]
  28. 28. 
    Cho J, Spence MM, Niu F, Hui RL, Gray P, Steinberg S 2020. Risk of overdose with exposure to prescription opioids, benzodiazepines, and non-benzodiazepine sedative-hypnotics in adults: a retrospective cohort study. J. Gen. Intern. Med. 35:696–703
    [Google Scholar]
  29. 29. 
    Choi H, Schoeni RF, Martin LG 2016. Are functional and activity limitations becoming more prevalent among 55 to 69-year-olds in the United States. ? PLOS ONE 11:e0164565
    [Google Scholar]
  30. 30. 
    Cicero TJ, Ellis MS, Surratt HL, Kurtz SP 2014. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry 71:821–26
    [Google Scholar]
  31. 31. 
    Compton WM, Jones CM, Baldwin GT 2016. Relationship between nonmedical prescription-opioid use and heroin use. N. Engl. J. Med. 374:154–63
    [Google Scholar]
  32. 32. 
    Connery HS. 2015. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harvard Rev. Psychiatry 23:63–75
    [Google Scholar]
  33. 33. 
    Dart RC, Severtson SG, Bucher-Bartelson B 2015. Trends in opioid analgesic abuse and mortality in the United States. N. Engl. J. Med. 372:1573–74
    [Google Scholar]
  34. 34. 
    Dasgupta N, Beletsky L, Ciccarone D 2018. Opioid crisis: no easy fix to its social and economic determinants. Am. J. Public Health 108:182–86
    [Google Scholar]
  35. 35. 
    Davis CS, Lieberman AJ, Hernandez-Delgado H, Suba C 2019. Laws limiting the prescribing or dispensing of opioids for acute pain in the United States: a national systematic legal review. Drug Alcohol Depend 194:166–72
    [Google Scholar]
  36. 36. 
    Davis CS, Piper BJ, Gertner AK, Rotter JS 2020. Opioid prescribing laws are not associated with short-term declines in prescription opioid distribution. Pain Med 21:532–37
    [Google Scholar]
  37. 37. 
    De Souza L, Frank AO 2011. Patients' experiences of the impact of chronic back pain on family life and work. Disabil. Rehabil. 33:310–18
    [Google Scholar]
  38. 38. 
    Dean A, Kimmel S. 2019. Free trade and opioid overdose death in the United States. SSM Popul. Health 8:100409
    [Google Scholar]
  39. 39. 
    Des Jarlais DC, Nugent A, Solberg A, Feelemyer J, Mermin J, Holtzman D 2015. Syringe service programs for persons who inject drugs in urban, suburban, and rural areas—United States, 2013. Morb. Mortal. Wkly. Rep. 64:1337–41
    [Google Scholar]
  40. 40. 
    Diez Roux AV. 2017. Despair as a cause of death: more complex than it first appears. Am. J. Public Health 107:1566–67
    [Google Scholar]
  41. 41. 
    Doleac JL, Mukherjee A. 2018. The moral hazard of lifesaving innovations: naloxone access, opioid abuse, and crime IZA Discuss. Pap. 11489 Inst. Labor Econ Bonn, Ger:.
  42. 42. 
    Dowell D, Haegerich TM, Chou R 2016. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. Morb. Mortal. Wkly. Rep. 65:1–49
    [Google Scholar]
  43. 43. 
    Dowell D, Zhang K, Noonan RK, Hockenberry JM 2016. Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates. Health Aff 35:1876–83
    [Google Scholar]
  44. 44. 
    Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD 2014. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin. J. Pain 30:557–64
    [Google Scholar]
  45. 45. 
    Evans TI, Hadland SE, Clark MA, Green TC, Marshall BDL 2016. Factors associated with knowledge of a Good Samaritan Law among young adults who use prescription opioids non-medically. Harm Reduct. J. 13:24
    [Google Scholar]
  46. 46. 
    Eyre E. 2020. Death in Mud Lick: A Coal Country Fight Against the Drug Companies That Delivered the Opioid Epidemic New York: Scribner
  47. 47. 
    Feder KA, Krawczyk N, Saloner B 2017. Medication-assisted treatment for adolescents in specialty treatment for opioid use disorder. J. Adolesc. Health 60:747–50
    [Google Scholar]
  48. 48. 
    Fink DS, Schleimer JP, Sarvet A, Grover KK, Delcher C et al. 2018. Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: a systematic review. Ann. Intern. Med. 168:783–90
    [Google Scholar]
  49. 49. 
    Ford JA, Hinojosa MS, Nicholson HL 2018. Disability status and prescription drug misuse among U.S. adults. Addict. Behav. 85:64–69
    [Google Scholar]
  50. 50. 
    Friedman SR, Mateu-Gelabert P, Curtis R, Maslow C, Bolyard M et al. 2007. Social capital or networks, negotiations, and norms? A neighborhood case study. Am. J. Prev. Med. 32:S160–70
    [Google Scholar]
  51. 51. 
    Friedmann PD, Hoskinson R, Gordon M, Schwartz R, Kinlock T et al. 2012. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst. Abuse 33:9–18
    [Google Scholar]
  52. 52. 
    Galea S, Ahern J, Tracy M, Vlahov D 2007. Neighborhood income and income distribution and the use of cigarettes, alcohol, and marijuana. Am. J. Prev. Med. 32:S195–202
    [Google Scholar]
  53. 53. 
    Gertner AK, Domino ME, Davis CS 2018. Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid. Drug Alcohol Depend 190:37–41
    [Google Scholar]
  54. 54. 
    Ghertner R, Groves L. 2018. Economic Opportunity and the Opioid Crisis: Geographic and Economic Trends Washington, DC: Off. Assist. Secr. Plan. Eval.
  55. 55. 
    Glazier RE, Kling RN. 2013. Recent trends in substance abuse among persons with disabilities compared to that of persons without disabilities. Disabil. Health J. 6:107–15
    [Google Scholar]
  56. 56. 
    Golub A, Johnson BD, Dunlap E 2005. Subcultural evolution and illicit drug use. Addict. Res. Theory 13:217–29
    [Google Scholar]
  57. 57. 
    Gross DP, Stephens B, Bhambhani Y, Haykowsky M, Bostick GP, Rashiq S 2009. Opioid prescriptions in Canadian workers' compensation claimants: prescription trends and associations between early prescription and future recovery. Spine 34:525–31
    [Google Scholar]
  58. 58. 
    Hadland SE, Cerdá M, Li Y, Krieger MS, Marshall BDL 2018. Association of pharmaceutical industry marketing of opioid products to physicians with subsequent opioid prescribing. JAMA Intern. Med. 178:861–63
    [Google Scholar]
  59. 59. 
    Haffajee RL, Bohnert ASB, Lagisetty PA 2018. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am. J. Prev. Med. 54:S230–42
    [Google Scholar]
  60. 60. 
    Haffajee RL, French CA. 2019. Provider perceptions of system-level opioid prescribing and addiction treatment policies. Curr. Opin. Psychol. 30:65–73
    [Google Scholar]
  61. 61. 
    Hagan H, McGough JP, Thiede H, Hopkins S, Duchin J, Alexander ER 2000. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J. Subst. Abuse Treat. 19:247–52
    [Google Scholar]
  62. 62. 
    Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C 2008. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am. J. Epidemiol. 168:1099–109
    [Google Scholar]
  63. 63. 
    Harduar Morano L, Steege AL, Luckhaupt SE 2018. Occupational patterns in unintentional and undetermined drug-involved and opioid-involved overdose deaths—United States, 2007–2012. Morb. Mortal. Wkly. Rep. 67:925–30
    [Google Scholar]
  64. 64. 
    Hawkins D, Roelofs C, Laing J, Davis L 2019. Opioid-related overdose deaths by industry and occupation—Massachusetts, 2011–2015. Am. J. Ind. Med. 62:815–25
    [Google Scholar]
  65. 65. 
    Hedegaard H, Miniño AM, Warner M 2020. Drug overdose deaths in the United States, 1999–2018 NCHS Data Br. 356 Natl. Cent. Health Stat., Cent. Dis. Control Prev., US Dep. Health Hum. Serv Hyattsville, MD:
  66. 66. 
    Hedegaard H, Warner M, Miniño AM 2017. Drug overdose deaths in the United States, 1999–2015 NCHS Data Br. 273 Natl. Cent. Health Stat., Cent. Dis. Control Prev., US Dep. Health Hum. Serv Hyattsville, MD:
  67. 67. 
    Health Justice Action Lab 2019. Drug-induced homicide Health in Justice, Northeastern Univ Boston:updated Sept. 18 https://www.healthinjustice.org/drug-induced-homicide
  68. 68. 
    Hollingsworth A, Ruhm CJ, Simon K 2017. Macroeconomic conditions and opioid abuse. J. Health Econ. 56:222–33
    [Google Scholar]
  69. 69. 
    Hughes C, Avoke SK. 2010. The elephant in the room: poverty, disability, and employment. Res. Pract. Pers. Severe Disabil. 35:5–14
    [Google Scholar]
  70. 70. 
    Huhn AS, Dunn KE. 2017. Why aren't physicians prescribing more buprenorphine. ? J. Subst. Abuse Treat. 78:1–7
    [Google Scholar]
  71. 71. 
    Inciardi JA, Surratt HL, Cicero TJ, Kurtz SP, Martin SS, Parrino MW 2009. The “black box” of prescription drug diversion. J. Addict. Dis. 28:332–47
    [Google Scholar]
  72. 72. 
    Jakubowski A, Fox A. 2020. Defining low-threshold buprenorphine treatment. J. Addict. Med. 14:95–98
    [Google Scholar]
  73. 73. 
    Jakubowski A, Kunins HV, Huxley-Reicher Z, Siegler A 2018. Knowledge of the 911 Good Samaritan Law and 911-calling behavior of overdose witnesses. Subst. Abuse 39:233–38
    [Google Scholar]
  74. 74. 
    Jenkins WD, Bolinski R, Bresett J, Van Ham B, Fletcher S et al. 2021. COVID-19 during the opioid epidemic—exacerbation of stigma and vulnerabilities. J. Rural Health 37:17274
    [Google Scholar]
  75. 75. 
    Jerry JM, Collins GB. 2013. Medication-assisted treatment of opiate dependence is gaining favor. Clevel. Clin. J. Med. 80:345–49
    [Google Scholar]
  76. 76. 
    Jones CW, Christman Z, Smith CM, Safferman MR, Salzman M et al. 2018. Comparison between buprenorphine provider availability and opioid deaths among US counties. J. Subst. Abuse Treat. 93:19–25
    [Google Scholar]
  77. 77. 
    Joshi S, Weiser T, Warren-Mears V 2018. Drug, opioid-involved, and heroin-involved overdose deaths among American Indians and Alaska Natives—Washington, 1999–2015. Morb. Mortal. Wkly. Rep. 67:1384–87
    [Google Scholar]
  78. 78. 
    Karamouzian M, Dohoo C, Forsting S, McNeil R, Kerr T, Lysyshyn M 2018. Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada. Harm Reduct. J. 15:46
    [Google Scholar]
  79. 79. 
    Kariisa M, Scholl L, Wilson N, Seth P, Hoots B 2019. Drug overdose deaths involving cocaine and psychostimulants with abuse potential—United States, 2003–2017. Morb. Mortal. Wkly. Rep. 68:388–95
    [Google Scholar]
  80. 80. 
    Kennedy MC, Karamouzian M, Kerr T 2017. Public health and public order outcomes associated with supervised drug consumption facilities: a systematic review. Curr. HIV/AIDS Rep. 14:161–83
    [Google Scholar]
  81. 81. 
    Kerensky T, Walley AY. 2017. Opioid overdose prevention and naloxone rescue kits: what we know and what we don't know. Addict. Sci. Clin. Pract. 12:4
    [Google Scholar]
  82. 82. 
    Kiang MV, Basu S, Chen J, Alexander MJ 2019. Assessment of changes in the geographical distribution of opioid-related mortality across the United States by opioid type, 1999–2016. JAMA Netw. Open 2:e190040
    [Google Scholar]
  83. 83. 
    Kidorf M, King VL, Gandotra N, Kolodner K, Brooner RK 2012. Improving treatment enrollment and re-enrollment rates of syringe exchangers: 12-month outcomes. Drug Alcohol Depend 124:162–66
    [Google Scholar]
  84. 84. 
    Knudsen HK, Abraham AJ, Oser CB 2011. Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure. Eval. Progr. Plan. 34:375–81
    [Google Scholar]
  85. 85. 
    Koester S, Mueller SR, Raville L, Langegger S, Binswanger IA 2017. Why are some people who have received overdose education and naloxone reticent to call Emergency Medical Services in the event of overdose. ? Int. J. Drug Policy 48:115–24
    [Google Scholar]
  86. 86. 
    Kolla G, Strike C, Watson TM, Jairam J, Fischer B, Bayoumi AM 2017. Risk creating and risk reducing: community perceptions of supervised consumption facilities for illicit drug use. Health Risk Soc 19:91–111
    [Google Scholar]
  87. 87. 
    Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL et al. 2015. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu. Rev. Public Health 36:559–74
    [Google Scholar]
  88. 88. 
    Kosten TR, George TP. 2002. The neurobiology of opioid dependence: implications for treatment. Sci. Pract. Perspect. 1:13–20
    [Google Scholar]
  89. 89. 
    Krawczyk N, Feder KA, Fingerhood MI, Saloner B 2017. Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample. Drug Alcohol Depend 178:512–18
    [Google Scholar]
  90. 90. 
    Krawczyk N, Fingerhood MI, Agus D 2020. Lessons from COVID 19: Are we finally ready to make opioid treatment accessible. ? J. Subst. Abuse Treat. 117:108074
    [Google Scholar]
  91. 91. 
    Krawczyk N, Mojtabai R, Stuart EA, Fingerhood M, Agus D et al. 2020. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction 115:1683–94
    [Google Scholar]
  92. 92. 
    Krawczyk N, Picher CE, Feder KA, Saloner B 2017. Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Aff 36:2046–53
    [Google Scholar]
  93. 93. 
    Krawczyk N, Schneider KE, Eisenberg MD, Richards TM, Ferris L et al. 2020. Opioid overdose death following criminal justice involvement: linking statewide corrections and hospital databases to detect individuals at highest risk. Drug Alcohol Depend 213:107997
    [Google Scholar]
  94. 94. 
    Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N et al. 2018. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann. Intern. Med. 169:137–45
    [Google Scholar]
  95. 95. 
    LaSalle L. 2017. An Overdose Death Is Not Murder: Why Drug-Induced Homicide Laws Are Counterproductive and Inhumane New York: Drug Policy Alliance
  96. 96. 
    Latimore AD, Bergstein RS. 2017. “Caught with a body” yet protected by law? Calling 911 for opioid overdose in the context of the Good Samaritan Law. Int. J. Drug Policy 50:82–89
    [Google Scholar]
  97. 97. 
    Lauer EA, Henly M, Brucker DL 2019. Prescription opioid behaviors among adults with and without disabilities—United States, 2015–2016. Disabil. Health J. 12:519–22
    [Google Scholar]
  98. 98. 
    Leshner AI, Dzau VJ. 2019. Medication-based treatment to address opioid use disorder. JAMA 321:2071–72
    [Google Scholar]
  99. 99. 
    Lippold KM, Jones CM, Olsen EO, Giroir BP 2019. Racial/ethnic and age group differences in opioid and synthetic opioid-involved overdose deaths among adults aged ≥ 18 years in metropolitan areas—United States, 2015–2017. Morb. Mortal. Wkly. Rep. 68:967–73
    [Google Scholar]
  100. 100. 
    Marlatt GA. 1996. Taxonomy of high-risk situations for alcohol relapse: evolution and development of a cognitive-behavioral model. Addiction 91:Suppl.S37–49
    [Google Scholar]
  101. 101. 
    Marlatt GA, Larimer ME, Witkiewitz K 2012. Harm Reduction: Pragmatic Strategies for Managing High-Risk Behaviors New York: Guilford. , 2nd. ed.
  102. 102. 
    Mars SG, Rosenblum D, Ciccarone D 2019. Illicit fentanyls in the opioid street market: desired or imposed. ? Addiction 114:774–80
    [Google Scholar]
  103. 103. 
    Martin LG, Freedman VA, Schoeni RF, Andreski PM 2010. Trends in disability and related chronic conditions among people ages fifty to sixty-four. Health Aff 29:725–31
    [Google Scholar]
  104. 104. 
    Martins SS, Ponicki W, Smith N, Rivera-Aguirre A, Davis CS et al. 2019. Prescription drug monitoring programs operational characteristics and fatal heroin poisoning. Int. J. Drug Policy 74:174–80
    [Google Scholar]
  105. 105. 
    Mauri AI, Townsend TN, Haffajee RL 2020. The association of state opioid misuse prevention policies with patient- and provider-related outcomes: a scoping review. Milbank Q 98:57–105
    [Google Scholar]
  106. 106. 
    McClellan C, Lambdin BH, Ali MM, Mutter R, Davis CS et al. 2018. Opioid-overdose laws association with opioid use and overdose mortality. Addict. Behav. 86:90–95
    [Google Scholar]
  107. 107. 
    McDonald R, Strang J. 2016. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction 111:1177–87
    [Google Scholar]
  108. 108. 
    McLean K. 2016. “There's nothing here”: deindustrialization as risk environment for overdose. Int. J. Drug Policy 29:19–26
    [Google Scholar]
  109. 109. 
    Meara E, Horwitz JR, Powell W, McClelland L, Zhou W et al. 2016. State legal restrictions and prescription-opioid use among disabled adults. N. Engl. J. Med. 375:44–53
    [Google Scholar]
  110. 110. 
    Merrall ELC, Kariminia A, Binswanger IA, Hobbs MS, Farrell M et al. 2010. Meta-analysis of drug-related deaths soon after release from prison. Addiction 105:1545–54
    [Google Scholar]
  111. 111. 
    Mojtabai R, Mauro C, Wall MM, Barry CL, Olfson M 2019. Medication treatment for opioid use disorders in substance use treatment facilities. Health Aff 38:14–23
    [Google Scholar]
  112. 112. 
    Monico LB, Gryczynski J, Mitchell SG, Schwartz RP, O'Grady KE, Jaffe JH 2015. Buprenorphine treatment and 12-step meeting attendance: conflicts, compatibilities, and patient outcomes. J. Subst. Abuse Treat. 57:89–95
    [Google Scholar]
  113. 113. 
    Monnat SM. 2018. Factors associated with county-level differences in U.S. drug-related mortality rates. Am. J. Prev. Med. 54:611–19
    [Google Scholar]
  114. 114. 
    Morden NE, Munson JC, Colla CH, Skinner JS, Bynum JPW et al. 2014. Prescription opioid use among disabled Medicare beneficiaries: intensity, trends, and regional variation. Med. Care 52:852–59
    [Google Scholar]
  115. 115. 
    Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY 2018. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J. Subst. Abuse Treat. 85:90–96
    [Google Scholar]
  116. 116. 
    Musto D. 1993. Drugs, Alcohol, and Tobacco: Making the Science and Policy Connections Oxford, UK: Oxford Univ. Press
  117. 117. 
    Nagelhout GE, Hummel K, de Goeij MCM, de Vries H, Kaner E, Lemmens P 2017. How economic recessions and unemployment affect illegal drug use: a systematic realist literature review. Int. J. Drug Policy 44:69–83
    [Google Scholar]
  118. 118. 
    Nahin RL, Sayer B, Stussman BJ, Feinberg TM 2019. Eighteen-year trends in the prevalence of, and health care use for, noncancer pain in the United States: data from the Medical Expenditure Panel Survey. J. Pain 20:796–809
    [Google Scholar]
  119. 119. 
    Netherland J, Hansen H. 2017. White opioids: pharmaceutical race and the war on drugs that wasn't. Biosocieties 12:217–38
    [Google Scholar]
  120. 120. 
    Ng J, Sutherland C, Kolber MR 2017. Does evidence support supervised injection sites. ? Can. Fam. Phys. Med. Fam. Can. 63:866
    [Google Scholar]
  121. 121. 
    Nosrati E, Kang-Brown J, Ash M, McKee M, Marmot M, King L 2019. Economic decline, incarceration, and mortality from drug use disorders in the USA between 1983 and 2014: an observational analysis. Lancet Public Health 4:e326–33
    [Google Scholar]
  122. 122. 
    Ompad DC, Gershon RR, Sandh S, Acosta P, Palamar JJ 2019. Construction trade and extraction workers: a population at high risk for drug use in the United States, 2005–2014. Drug Alcohol Depend 205:107640
    [Google Scholar]
  123. 123. 
    Patrick SW, Schiff DM. 2017. A public health response to opioid use in pregnancy. Pediatrics 139:e20164070
    [Google Scholar]
  124. 124. 
    PDAPS (Prescr. Drug Abuse Policy Syst.) 2017. Naloxone overdose prevention laws PDAPS Philadelphia:updated July 1 http://pdaps.org/datasets/laws-regulating-administration-of-naloxone-1501695139
  125. 125. 
    PDAPS (Prescr. Drug Abuse Policy Syst.) 2018. Good Samaritan overdose prevention laws PDAPS Philadelphia:updated July 1 http://pdaps.org/datasets/good-samaritan-overdose-laws-1501695153
  126. 126. 
    Pearl J. 2018. Does obesity shorten life? Or is it the soda? On non-manipulable causes. J. Causal Inference 6:20182001
    [Google Scholar]
  127. 127. 
    Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE 2019. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the Southeastern United States. Int. J. Drug Policy 63:122–28
    [Google Scholar]
  128. 128. 
    Pierce JR, Schott PK. 2020. Trade liberalization and mortality: evidence from US counties. Am. Econ. Rev. Insights 2:47–64
    [Google Scholar]
  129. 129. 
    Pitcher MH, Von Korff M, Bushnell MC, Porter L 2019. Prevalence and profile of high-impact chronic pain in the United States. J. Pain 20:146–60
    [Google Scholar]
  130. 130. 
    Popovici I, Maclean JC, Hijazi B, Radakrishnan S 2018. The effect of state laws designed to prevent nonmedical prescription opioid use on overdose deaths and treatment. Health Econ 27:294–305
    [Google Scholar]
  131. 131. 
    Rees DI, Sabia JJ, Argys LM, Dave D, Latshaw J 2019. With a little help from my friends: the effects of Good Samaritan and naloxone access laws on opioid‐related deaths. J. Law Econ. 62:1–27
    [Google Scholar]
  132. 132. 
    Rigg KK, March SJ, Inciardi JA 2010. Prescription drug abuse & diversion: role of the pain clinic. J. Drug Issues 40:681–702
    [Google Scholar]
  133. 133. 
    Rosenblum D, Unick GJ, Ciccarone D 2014. The entry of Colombian-sourced heroin into the US market: the relationship between competition, price, and purity. Int. J. Drug Policy 25:88–95
    [Google Scholar]
  134. 134. 
    Rosenblum D, Unick J, Ciccarone D 2017. An instrumental variables approach to estimating the effects of changes in the heroin market on overdose in the US Work. Pap. 170011 Can. Cent. Health Econ Toronto:
  135. 135. 
    Rosenfeld M. 2011. State pain laws: a case for intractable pain centers part III. Pract. Pain Manag. 5: https://www.practicalpainmanagement.com/resources/ethics/state-pain-laws-case-intractable-pain-centers-part-iii
    [Google Scholar]
  136. 136. 
    Rudd RA, Aleshire N, Zibbell JE, Gladden RM 2016. Increases in drug and opioid overdose deaths—United States, 2000–2014. Morb. Mortal. Wkly. Rep. 64:1378–82
    [Google Scholar]
  137. 137. 
    Rudd RA, Seth P, David F, Scholl L 2016. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. Morb. Mortal. Wkly. Rep. 65:1445–52
    [Google Scholar]
  138. 138. 
    Rudolph KE, Kinnard EN, Aguirre AR, Goin DE, Feelemyer J et al. 2020. The relative economy and drug overdose deaths. Epidemiology 31:551–58
    [Google Scholar]
  139. 139. 
    Rutkow L, Vernick JS, Alexander GC 2017. More states should regulate pain management clinics to promote public health. Am. J. Public Health 107:240–43
    [Google Scholar]
  140. 140. 
    Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G 2018. Drug and opioid-involved overdose deaths—United States, 2013–2017. Morb. Mortal. Wkly. Rep. 67:1419–27
    [Google Scholar]
  141. 141. 
    Shackford S. 2020. Philadelphia safe injection site opening delayed. Reason March 2. https://reason.com/2020/03/02/philadelphia-safe-injection-site-opening-delayed/
    [Google Scholar]
  142. 142. 
    Sigmon SC. 2014. Access to treatment for opioid dependence in rural America: challenges and future directions. JAMA Psychiatry 71:359–60
    [Google Scholar]
  143. 143. 
    Song Z. 2017. Mortality quadrupled among opioid-driven hospitalizations, notably within lower-income and disabled white populations. Health Aff 36:2054–61
    [Google Scholar]
  144. 144. 
    Spencer MR, Warner M, Bastian BA, Trinidad JP, Hedegaard H 2019. Drug overdose deaths involving fentanyl, 2011–2016 Natl. Vital Stat. Rep. 68 Natl. Cent. Health Stat., Cent. Dis. Control Prev., US Dep. Health Hum. Serv Hyattsville, MD:
  145. 145. 
    Staton LJ, Panda M, Chen I, Genao I, Kurz J et al. 2007. When race matters: disagreement in pain perception between patients and their physicians in primary care. J. Natl. Med. Assoc. 99:532–38
    [Google Scholar]
  146. 146. 
    Stein EM, Gennuso KP, Ugboaja DC, Remington PL 2017. The epidemic of despair among White Americans: trends in the leading causes of premature death, 1999–2015. Am. J. Public Health 107:1541–47
    [Google Scholar]
  147. 147. 
    Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C 2016. Retention in medication-assisted treatment for opiate dependence: a systematic review. J. Addict. Dis. 35:22–35
    [Google Scholar]
  148. 148. 
    Turner B, Turner R. 2004. Physical disability, unemployment, and mental health. Rehabil. Psychol. 49:241–49
    [Google Scholar]
  149. 149. 
    Unick GJ, Ciccarone D. 2017. US regional and demographic differences in prescription opioid and heroin-related overdose hospitalizations. Int. J. Drug Policy 46:112–19
    [Google Scholar]
  150. 150. 
    Unick GJ, Rosenblum D, Mars S, Ciccarone D 2014. The relationship between US heroin market dynamics and heroin-related overdose, 1992–2008. Addiction 109:1889–98
    [Google Scholar]
  151. 151. 
    US Dep. Health Hum. Serv 2016. National Pain Strategy: a comprehensive population health strategy for pain Rep., Interagency Pain Res. Coord. Comm., Natl. Inst. Health Bethesda, MA: https://iprcc.nih.gov/sites/default/files/HHSNational_Pain_Strategy_508C.pdf
  152. 152. 
    Van Zee A. 2009. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am. J. Public Health 99:221–27
    [Google Scholar]
  153. 153. 
    Venkataramani AS, Bair EF, O'Brien RL, Tsai AC 2020. Association between automotive assembly plant closures and opioid overdose mortality in the United States: a difference-in-differences analysis. JAMA Int. Med. 180:254–62
    [Google Scholar]
  154. 154. 
    Volkow N, Benveniste H, McLellan AT 2018. Use and misuse of opioids in chronic pain. Annu. Rev. Med. 69:451–65
    [Google Scholar]
  155. 155. 
    Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN 2015. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 156:569–76
    [Google Scholar]
  156. 156. 
    Wakeman SE. 2016. Using science to battle stigma in addressing the opioid epidemic: Opioid agonist therapy saves lives. Am. J. Med. 129:455–56
    [Google Scholar]
  157. 157. 
    Webster BS, Verma SK, Gatchel RJ 2007. Relationship between early opioid prescribing for acute occupational low back pain and disability duration, medical costs, subsequent surgery and late opioid use. Spine 32:2127–32
    [Google Scholar]
  158. 158. 
    Werb D, Kerr T, Nosyk B, Strathdee S, Montaner J, Wood E 2013. The temporal relationship between drug supply indicators: an audit of international government surveillance systems. BMJ Open 3:e003077
    [Google Scholar]
  159. 159. 
    Whitney DG, Hurvitz EA, Peterson MD 2020. Cardiometabolic disease, depressive symptoms, and sleep disorders in middle-aged adults with functional disabilities: NHANES 2007–2014. Disabil. Rehabil. 42:2186–91
    [Google Scholar]
  160. 160. 
    WHO (World Health Organ.) 2014. Community management of opioid overdose Rep., WHO Atlanta: https://www.who.int/publications/i/item/9789241548816
  161. 161. 
    Williams AR, Nunes EV, Bisaga A, Levin FR, Olfson M 2019. Development of a Cascade of Care for responding to the opioid epidemic. Am. J. Drug Alcohol Abuse 45:1–10
    [Google Scholar]
  162. 162. 
    Wilson HD, Mayer TG, Gatchel RJ 2011. The lack of association between changes in functional outcomes and work retention in a chronic disabling occupational spinal disorder population: implications for the minimum clinical important difference. Spine 36:474–80
    [Google Scholar]
  163. 163. 
    Wilson N, Kariisa M, Seth P, Smith H IV, Davis NL 2020. Drug and opioid-involved overdose deaths—United States, 2017–2018. Morb. Mortal. Wkly. Rep. 69:290–97
    [Google Scholar]
  164. 164. 
    Wilson WJ. 1996. When Work Disappears: The World of the New Urban Poor New York: Knopf
  165. 165. 
    Wong CY, Zhu W, Aurigemma GP, Furukawa N, Teshale EH et al. 2020. Infective endocarditis among persons aged 18–64 years with HIV, hepatitis C infection, or opioid use disorder—United States, 2007–2017. Clin. Infect. Dis. In press. https://doi.org/10.1093/cid/ciaa372
    [Crossref] [Google Scholar]
  166. 166. 
    Xu J, Davis CS, Cruz M, Lurie P 2018. State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. Drug Alcohol Depend 189:37–41
    [Google Scholar]
  167. 167. 
    Zepinic V, Kuzmanovski B. 2019. Chronic pain and depression in low back (spinal) injured patients. Am. J. Appl. Psychol. 8:89–97
    [Google Scholar]
  168. 168. 
    Zoorob MJ, Salemi JL. 2017. Bowling alone, dying together: the role of social capital in mitigating the drug overdose epidemic in the United States. Drug Alcohol Depend 173:1–9
    [Google Scholar]
/content/journals/10.1146/annurev-publhealth-090419-102727
Loading
  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error